Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 10/20 | 0.88 |
| ▸ | F2 | P00734 | 2/20 | 0.61 |
| ▸ | F10 | P00742 | 2/20 | 0.61 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.49 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.49 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8815310 | 1.00 | PRMT1 (0.88) | PRMT1F2F10TPSAB1TPSD1 | |
| SCHEMBL7979972 | 1.00 | PRMT1 (0.88) | PRMT1F2F10TPSAB1TPSD1 | |
| SCHEMBL12412056 | 0.94 | PRMT1 (1.00) | PRMT1F2F10TPSAB1TPSD1 | |
| SCHEMBL8229718 | 0.93 | PRMT1 (0.89) | PRMT1F2F10TPSAB1TPSD1 | |
| SCHEMBL20184755 | 0.92 | PRMT1 (1.00) | PRMT1F2F10PLGPLAU | |
| SCHEMBL8229699 | 0.92 | PRMT1 (0.86) | PRMT1F2F10TPSAB1TPSD1 | |
| SCHEMBL20184763 | 0.87 | PRMT1 (1.00) | PRMT1F2F10PLGPLAU | |
| SCHEMBL20184756 | 0.86 | PRMT1 (1.00) | PRMT1F2F10PLGPLAU | |
| SCHEMBL8235618 | 0.85 | PRMT1 (0.84) | PRMT1F2F10TPSAB1TPSD1 | |
| SCHEMBL8229704 | 0.85 | PRMT1 (1.00) | PRMT1F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945209-B1 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | US GOV AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U S ARMY MEDICAL RESEARCH (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20150259326-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-09-17 | — | — | US | disclosed |
| US-20150259326-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259326-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | ING2, GMFG, PLP2 | PRMT1 2298/4885F2 4794/4885F10 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.